查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571645

腫瘤分析市場規模、佔有率、趨勢分析報告：按方法、按技術、按應用、按地區、細分市場預測，2024-2030 年

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine, Oncological Diagnostics, Research), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

腫瘤分析市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球腫瘤分析市場規模預計將達到217.3億美元，2024年至2030年複合年成長率為10.3%。

預計增加體學科學在癌症檢測的應用研究將影響市場成長。

生物技術的進步使我們能夠深入了解新陳代謝和基因表現。這些正在加速代謝體學和表觀遺傳學等先進技術在癌症篩檢和檢測中的應用。因此，隨著下游應用的擴展，癌症腫瘤/分析（CTP）技術的需求預計將良好成長。

癌症腫瘤分析是一種潛在的方法，可以進一步研究它以檢測癌症並識別腫瘤階段、代謝和形態的變化。這對於常規診斷和治療決策很有用。腫瘤分析對於根據疾病嚴重程度和個體基因組圖譜開發針對特定個體的治療方法具有重要意義。

NGS 和原位雜合技術等檢測和測序技術的增強將有助於加快癌症腫瘤分析過程，預計將在未來幾年獲得顯著的發展。這些高採用率是由於以最少的資源和更高的準確性獲得結果的速度加快。

腫瘤分析市場的報告亮點

  • 個人化癌症醫學預計將成為採用 CTP 的最有利的應用領域。
  • 由於從癌細胞的基因組、表觀基因和代謝組學分析中獲得的功能資訊的不同用途和相互依賴性，預計這些技術領域將相互協同發展，並在預測期內表現出良好的成長。
  • 由於主要經濟體的各種發展以及新興經濟體領先企業的日益突出，預計亞太地區在未來十年將經歷顯著成長。
  • 主要企業包括 Illumina, Inc.、Qiagen NV、Neogenomics Laboratories Inc.、HTG Molecular Diagnostics, Inc.、Genomic Health Inc.、Caris Life Sciences Helomics Corporation、Nanostring Technologies、Oxford Gene Technology、Ribomed Biotechnologies, Inc.、nosPersonal Genome Diagtics 、GenomeDX、Guardant Health、基礎醫學等。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章腫瘤分析市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 腫瘤分析市場分析工具
    • 波特的分析
    • PESTEL分析

第4章腫瘤分析市場：方法估計與趨勢分析

  • 細分儀表板
  • 腫瘤分析市場：方法變異分析，百萬美元，2023 年和 2030 年
  • 基因組學
  • 蛋白質體學
  • 代謝體學
  • 表觀遺傳學

第5章腫瘤譜分析市場：技術評估與趨勢分析

  • 細分儀表板
  • 腫瘤分析市場：技術變遷分析，百萬美元，2023-2030
  • 定序技術
  • 原位雜合技術
  • 免疫組織化學
  • 定量PCR
  • 微陣列

第6章 腫瘤分析市場：應用估算與趨勢分析

  • 細分儀表板
  • 腫瘤分析市場：應用變化分析，百萬美元，2023-2030
  • 個人化癌症治療
  • 腫瘤診斷
  • 研究
    • 癌症研究
    • 生物標記發現

第7章腫瘤分析市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的腫瘤分析市場佔有率，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Illumina, Inc.
    • QIAGEN
    • Genomic Health
    • Neogenomics Inc.
    • Life Sciences
    • Oxford Gene Technology
    • Bruker Spatial Biology, Inc.
    • Ribomed Biotechnologies Inc.
    • GenomeDX
    • Guardant Health
    • FOUNDATION MEDICINE, INC.
簡介目錄
Product Code: GVR-2-68038-625-7

Tumor Profiling Market Growth & Trends:

The global tumor profiling market size is expected to reach USD 21.73 billion by 2030, expanding at a CAGR of 10.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Tumor Profiling Market Report Highlights:

  • Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption.
  • Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
  • Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well
  • Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tumor Profiling Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Tumor Profiling Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tumor Profiling Market: Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Tumor Profiling Market: Technique Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Genomics
    • 4.3.1. Genomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Proteomics
    • 4.4.1. Proteomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Metabolomics
    • 4.5.1. Metabolomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Epigenetics
    • 4.6.1. Epigenetics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tumor Profiling Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Tumor Profiling Market: Technology Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Sequencing Techniques
    • 5.3.1. Sequencing Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. NGS
      • 5.3.2.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Sanger Sequencing
      • 5.3.3.1. Sanger Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Pyro Sequencing
      • 5.3.4.1. Pyro Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. In Situ Hybridization
    • 5.4.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Immunohistochemistry
    • 5.5.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. qPCR
    • 5.6.1. qPCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Microarray
    • 5.7.1. Microarray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tumor Profiling Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Tumor Profiling Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Personalized Cancer Medicine
    • 6.3.1. Personalized Cancer Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oncological Diagnostics
    • 6.4.1. Oncological Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Cancer Research
      • 6.5.2.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Biomarker Discovery
      • 6.5.3.1. Biomarker Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tumor Profiling Market: Regional Estimates & Trend Analysis

  • 7.1. Tumor Profiling Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Illumina, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. QIAGEN
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Genomic Health
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Neogenomics Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Life Sciences
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Oxford Gene Technology
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bruker Spatial Biology, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Ribomed Biotechnologies Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GenomeDX
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Guardant Health
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. FOUNDATION MEDICINE, INC.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives